ARTICLE | Clinical News

CGF166: Phase I/II started

November 10, 2014 8:00 AM UTC

Novartis began an open-label, U.S. Phase I/II trial to evaluate single ascending doses of CGF166 given via intra-labyrinthine infusion in about 45 patients ages 21-70. The start of the trial triggered a $3 million milestone payment to GenVec under a 2010 deal granting Novartis exclusive, worldwide rights to its preclinical hearing loss and balance disorders program (see BioCentury, Jan. 25, 2010). ...